These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30014494)

  • 1. Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B.
    Chu CM; Liaw YF
    Hepatology; 2019 Jun; 69(6):2711. PubMed ID: 30014494
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B.
    Kim SE
    Korean J Intern Med; 2017 Jul; 32(4):631-633. PubMed ID: 28704912
    [No Abstract]   [Full Text] [Related]  

  • 3. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establish a predictive modeling under antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B].
    Liu GW; Tang KC; Li Q; Lu W
    Zhonghua Gan Zang Bing Za Zhi; 2018 Sep; 26(9):641-645. PubMed ID: 30481858
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Jiang JF; Sun J; Shi J; Liu X
    Aliment Pharmacol Ther; 2017 May; 45(9):1286-1288. PubMed ID: 28370051
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - authors' reply.
    Gounder PP; Mosites EM; McMahon BJ
    Aliment Pharmacol Ther; 2017 May; 45(9):1288-1289. PubMed ID: 28370054
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.
    Chen YC; Liaw YF
    Aliment Pharmacol Ther; 2016 Jul; 44(2):210-1. PubMed ID: 27296691
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?
    Liao YY; Ahir BK; Mo HY; Li LQ; Peng NF
    Aliment Pharmacol Ther; 2016 Oct; 44(8):908-10. PubMed ID: 27634236
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model.
    Tada T; Kumada T; Toyoda H; Ohisa M; Akita T; Tanaka J
    J Gastroenterol; 2018 Nov; 53(11):1196-1205. PubMed ID: 29675604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Authors' reply.
    Wong GL; Wong VW
    Aliment Pharmacol Ther; 2016 Oct; 44(8):910. PubMed ID: 27634237
    [No Abstract]   [Full Text] [Related]  

  • 12. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Chen CJ
    Gut; 2018 Apr; 67(4):595-598. PubMed ID: 29367206
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: reduction in chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low-risk patients - more questions than answers.
    Wei TY; Wang CC
    Aliment Pharmacol Ther; 2017 Jan; 45(1):185-186. PubMed ID: 27910147
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
    Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological Determinants of Spontaneous Postpartum e Antigen Seroconversion and Surface Antigen Seroclearance in Pregnant Women Infected with Hepatitis B Virus.
    Hu Y; Feng Z; Liu J; Chen J; Zhang S; Zhou YH
    Arch Med Res; 2016 Apr; 47(3):207-13. PubMed ID: 27387022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy for chronic hepatitis B.
    Jafri SM; Lok AS
    Clin Liver Dis; 2010 Aug; 14(3):425-38. PubMed ID: 20638023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
    Huang R; Liu J; Wang J; Yan X; Wu C
    Aliment Pharmacol Ther; 2021 Mar; 53(6):761-762. PubMed ID: 33599329
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B e Antigen--the dangerous endgame of hepatitis B.
    Liang TJ; Ghany M
    N Engl J Med; 2002 Jul; 347(3):208-10. PubMed ID: 12124411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.